Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

Tirzepatide Dosing Protocol: 5 mg Vial — Week-by-Week Titration & Supplies

Precise titration schedule, reconstitution steps, and supplies checklist for the 5 mg tirzepatide compounded vial.

Quickstart highlights

Tirzepatide activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, producing synergistic effects on insulin secretion, glucagon suppression, gastric emptying delay, and hypothalamic satiety signaling.

  • Concentration: 5 mg/mL (5 mg vial + 1 mL bacteriostatic water).
  • At 5 mg/mL on a U-100 syringe: 2.5 mg = 50 units, 5 mg = 100 units.
  • Starting dose: 2.5 mg (50 units) once weekly for 4 weeks; increase by 2.5 mg every 4 weeks.
  • One 5 mg vial covers 2 injections at the starting 2.5 mg dose.
  • Refrigerate reconstituted solution; use within 28 days.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-4250050Once weeklyStarting dose — use 100-unit U-100 syringe; inject subcutaneously
5-85000100Once weeklyFirst increase — 1 full vial dose; switch to new vial for week 5
9-127500150Once weekly7.5 mg dose requires second vial; reconstitute fresh vial at week 9
13-1610000200Once weekly10 mg maintenance — assess tolerability before increasing
17+12500250Once weekly12.5–15 mg optional maximum; titrate only if tolerating lower dose well

Gradual approach

WeekDose (µg)UnitsNotes
1-8250050Slow ramp — hold 2.5 mg for 8 weeks to minimize GI side effects
9-1650001005 mg plateau — reassess tolerability before advancing

Reconstitution steps

  1. Draw 1 mL bacteriostatic water into a 3 mL syringe; inject slowly down the vial wall to avoid foaming.
  2. Gently swirl — do not shake — until the lyophilized cake is fully dissolved (1–3 minutes).
  3. Solution should appear clear and colorless; discard if cloudy or particulate matter is visible.
  4. Label the vial with reconstitution date; refrigerate immediately at 2–8 °C.

Supplies needed

8-week plan

  • 2 vials
  • 8 syringes
  • 2 mL bac water
  • 8 alcohol swabs

12-week plan

  • 3 vials
  • 12 syringes
  • 3 mL bac water
  • 12 alcohol swabs

16-week plan

  • 4 vials
  • 16 syringes
  • 4 mL bac water
  • 16 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Support medically supervised weight management via dual GIP/GLP-1 receptor agonism with the slowest possible titration schedule to minimize GI adverse events. Target maintenance dose 10–15 mg weekly after 12–16 weeks.

Cycle length: 16 weeks on.

Off-cycle: 8–12 weeks off; monitor HbA1c, body weight, and appetite during off-cycle to assess need for re-initiation.

Storage & handling

Lyophilized: store in cool, dry place below 25 °C until reconstitution. Reconstituted: refrigerate at 2–8 °C; use within 28 days. Do not freeze reconstituted solution. Protect from light.

Injection & tracking tips

  • Inject subcutaneously in the abdomen (2 inches from navel), outer thigh, or upper arm; rotate sites each week.
  • Use a 100-unit (1 mL) U-100 insulin syringe for all doses; the 2.5 mg starting dose is exactly 50 units.
  • Inject at the same time each week (±24 hours acceptable); morning injection minimizes meal-timing conflicts.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Log body weight every Monday before eating; track weekly trend rather than daily fluctuation.
  • Record GI symptoms (nausea, vomiting, diarrhea) severity (0–10) after each injection.
  • Track fasting glucose weekly if diabetic or pre-diabetic; adjust hypoglycemic medications with your provider.
Log your cycle in the calculator →

How this works & references

Tirzepatide activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, producing synergistic effects on insulin secretion, glucagon suppression, gastric emptying delay, and hypothalamic satiety signaling. In the SURMOUNT-1 trial (NCT04184622, n=2,539), the 15 mg dose produced a mean 20.9% body weight reduction at 72 weeks versus 3.1% with placebo. The SURMOUNT-2 trial (NCT04657003) in type 2 diabetes showed 15.7% weight reduction at 72 weeks. GIP receptor co-agonism differentiates tirzepatide from pure GLP-1 agonists, as GIP signaling increases adipocyte energy expenditure and may reduce GLP-1-associated nausea.

Frequently asked questions

How many 5 mg vials do I need for a 16-week cycle?
Approximately 4 vials: 2 vials for weeks 1–8 at 2.5 mg/dose (2 doses per vial), and 1 vial per week once you exceed the 5 mg dose starting at week 5+. Exact count depends on your titration speed.
What if I experience severe nausea at 5 mg?
Pause the dose increase and maintain the last tolerated dose for an additional 2–4 weeks. Approximately 4.3% of participants in SURMOUNT-1 discontinued due to GI adverse events; nausea was most common during the first 4–8 weeks.
Can I inject at any time of day?
Yes — tirzepatide can be injected at any time of day, with or without meals. Consistency matters more than timing; the ±24-hour window is acceptable within each weekly interval.
What is the maximum dose for the 5 mg vial concentration?
At 5 mg/mL, one full 1 mL syringe delivers 5 mg (100 units). For doses above 5 mg, you will draw from two syringes or reconstitute a higher-concentration vial. Most protocols cap at 15 mg/week.
How should I handle a missed dose?
Inject the missed dose as soon as possible if more than 4 days remain until your next scheduled injection; otherwise skip and resume the regular weekly schedule. Never double-dose.

Related protocols

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.